{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:30:41Z","timestamp":1774438241382,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mast cells are closely associated with epithelium, serving as sentinels responsible for the recognition of tissue injury and coordination of the initial inflammatory response. Upon detection of the injured cell content, mast cells then tailor the release of preformed and newly produced chemical mediators to the detected challenge, via an array of pathogen receptors. In addition to immunoglobulin E receptor-triggered mast cell activation, commonly referred to as allergic or atopic disorders, non-immunoglobulin E receptor mediated mast cell activation follows engagement of toll-like receptors, immunoglobulin G receptors, and complement receptors. Upon containment of the extrinsic challenge, acute inflammation is downregulated, and repair of the injured tissue ensues. The mast cell compartments must return to a baseline steady state to remain tolerant towards self-antigens and harmless entities, including environmental conditions, to prevent unnecessary immune activation and chronic hypersensitivity disorders. Over the past 50\u00a0years, an increasing number of patients are experiencing episodes of aberrant mast cell activation, not associated with allergen-specific mast cell disease or systemic mastocytosis. This led to proposed diagnostic criteria of mast cell activation syndrome. Mast cell activation syndrome is a heterogeneous disorder, defined by a combination of (1) recurrent symptoms typical of mast cell activation, (2) an increase of validated mast cell derived mediators, and (3) response to treatment with mast cell stabilizing or mast cell mediator-targeted therapies. Onset of mast cell activation syndrome ostensibly reflects the loss of tolerance in the mast cell compartment to nonthreatening entities and nonhazardous environmental conditions. The etiology of chronic mast cell dysregulation and associated intolerance to self-antigens or harmless entities is not well understood, but a growing number of studies point to exposure of the epithelial borders, which leads to inappropriate or excessive mast cell activation or impaired resolution of acute inflammation following neutralization of the identified pathogen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>Here we present a case of adult onset mast cell activation syndrome following scombroid poisoning. Scombroid toxicity is usually a self-limited illness, but there are individuals who have been shown to have severe symptoms or persistent illness following histamine fish poisoning. We describe a 74-year-old Caucasian woman, with a history of drug-induced urticaria, who developed a constellation of hypersensitivity illnesses consistent with the diagnosis of mast cell activation syndrome after ingestion of tainted fish.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Mast cell activation disease causes problems of increased complexity in children and adults. The increased prevalence and severity of mast cell activation disease has been attributed to dramatic changes in our lifestyles and modern living environments. These changes likely impact the integrity of the epithelial barriers, leading to loss of tolerance in the mast cell compartment. Here, we present a case of a nonatopic, 74-year-old female who developed mast cell activation disease after exposure to a potent environmental toxin. Mast cell activation disease commonly involves several organ systems, with patients often referred to a succession of different specialists. This results in delayed diagnosis and suboptimal care. Instead, early recognition of mast cell activation disease would lead to better outcomes. We review the literature, describing the diagnostic criteria for mast cell activation disorders that can improve recognition of this multiorgan system syndrome. Further research is needed into the interaction of epithelial barrier disruption and the dysregulation of the immune system.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-021-03190-w","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T19:03:38Z","timestamp":1639767818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Adult-onset mast cell activation syndrome following scombroid poisoning: a case report and review of the literature"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4144-9763","authenticated-orcid":false,"given":"Isabelle","family":"Brock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Eng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Maitland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,18]]},"reference":[{"key":"3190_CR1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/S1081-1206(10)63560-0","volume":"96","author":"DH Dreyfus","year":"2006","unstructured":"Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol. 2006;96:624\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3190_CR2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jaci.2017.06.007","volume":"140","author":"C Akin","year":"2017","unstructured":"Akin C. Mast cell activation syndromes. J Allergy Clin Immunol. 2017;140:349\u201355.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"3190_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.iac.2018.04.002","volume":"38","author":"MJ Hamilton","year":"2018","unstructured":"Hamilton MJ. Non-clonal mast cell activation syndrome: a growing body of evidence. Immunol Allergy Clin North Am. 2018;38(3):469\u201381.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"6","key":"3190_CR4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1503\/cmaj.111031","volume":"184","author":"P Stratta","year":"2012","unstructured":"Stratta P, Badino G. Scombroid poisoning. Can Med Assoc J. 2012;184(6):674.","journal-title":"Can Med Assoc J"},{"key":"3190_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.toxicon.2010.02.006","volume":"56","author":"JM Hungerford","year":"2010","unstructured":"Hungerford JM. Scombroid poisoning. Toxicon. 2010;56:231\u201343.","journal-title":"Toxicon"},{"key":"3190_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0091-6749(97)70263-X","volume":"100","author":"IM Sanchez-Guerrero","year":"1997","unstructured":"Sanchez-Guerrero IM, Vidal JB, Escudero AI. Scombroid fish poisoning: a potentially life-threatening allergic-like reaction. J Allergy Clin Immunol. 1997;100:433\u20134.","journal-title":"J Allergy Clin Immunol"},{"key":"3190_CR7","first-page":"1","volume":"76","author":"G-S Lohiya","year":"2015","unstructured":"Lohiya G-S, Lohiya S, Lohiya S, Krishna V. Scrombrotoxinism: protracted illness following misdaignosis in the emergency department. Case Rep Emerg Med. 2015;76:1\u20134.","journal-title":"Case Rep Emerg Med."},{"key":"3190_CR8","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s11606-012-1996-6","volume":"27","author":"BJ Wilson","year":"2012","unstructured":"Wilson BJ, Musto RJ, Ghali W. A case of histamine fish poisoning in a young atopic woman. J Gen Intern Med. 2012;27:878\u201381.","journal-title":"J Gen Intern Med"},{"key":"3190_CR9","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jaci.2007.07.033","volume":"120","author":"FD Finkelman","year":"2007","unstructured":"Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol. 2007;120:506\u201315.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3190_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jaci.2015.03.048","volume":"136","author":"TAE Platts-Mills","year":"2015","unstructured":"Platts-Mills TAE. The allergy epidemics: 1870\u20132010. J Allergy Clin Immunol. 2015;136(1):3\u201313. https:\/\/doi.org\/10.1016\/j.jaci.2015.03.048.","journal-title":"J Allergy Clin Immunol"},{"key":"3190_CR11","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.080612","author":"P Subbarao","year":"2009","unstructured":"Subbarao P, Mandhane PJ, Sears MR. Asthma: epidemiology, etiology and risk factors. CMAJ. 2009. https:\/\/doi.org\/10.1503\/cmaj.080612.","journal-title":"CMAJ"},{"issue":"4","key":"3190_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jaci.2019.08.023","volume":"144","author":"CR Weiler","year":"2019","unstructured":"Weiler CR, Austen KF, Akin C, Barkoff MS, Bernstein JA, Bonadonna P, Schwartz LB, et\u00a0al. AAAAI mast cell disorders committee work group report: mast cell activation syndrome (MCAS) diagnosis and management. J Allergy Clin Immunol. 2019;144(4):883\u201393.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"3190_CR13","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jaip.2018.11.045","volume":"7","author":"P Valent","year":"2019","unstructured":"Valent P, Akin C. Doctor, I think I am suffering from MCAS: differential diagnosis and separating facts from fiction. J Allergy Clin Immunol Pract. 2019;7(4):1109\u201314. https:\/\/doi.org\/10.1016\/j.jaip.2018.11.045.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"3190_CR14","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.jaci.2017.04.010","volume":"139","author":"RP Schleimer","year":"2017","unstructured":"Schleimer RP, Berdnikovs S. Etiology of epithelial barrier dysfunction in type 2 inflammatory diseases. J Allergy Clin Immunol. 2017;139(6):1752\u201361.","journal-title":"J Allergy Clin Immunol"},{"key":"3190_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1056\/NEJMra1409760","volume":"373","author":"TC Theoharides","year":"2015","unstructured":"Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med. 2015;373:163\u201372. https:\/\/doi.org\/10.1056\/NEJMra1409760.","journal-title":"N Engl J Med"},{"key":"3190_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jaip.2013.06.003","volume":"1","author":"D Kahn","year":"2013","unstructured":"Kahn D. Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use. J Allergy Clin Immunol Pract. 2013;1:433\u201340.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3190_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/B978-0-12-386037-8.00006-5","volume":"290","author":"G Chieffi Baccari","year":"2011","unstructured":"Chieffi Baccari G, Pinelli C, Santillo A, Minucci S, Rastogi RK. Mast cells in nonmammalian vertebrates: an overview. Int rev Cell Mol Bio. 2011;290:1\u201353.","journal-title":"Int rev Cell Mol Bio"},{"issue":"7","key":"3190_CR18","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1002\/eji.201040559","volume":"40","author":"SJ Galli","year":"2010","unstructured":"Galli SJ, Tsai M. Mast cells in allergy and infection: versatile effector and regulatory cells in innate and acquired immunity. Eur J Immunol. 2010;40(7):1843\u201351.","journal-title":"Eur J Immunol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-03190-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-021-03190-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-03190-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T19:03:50Z","timestamp":1639767830000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-03190-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3190"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-03190-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-415528\/v1","asserted-by":"object"}]},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"11 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval and consent to participate was given by the patient","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Isabelle Brock has no conflicts to declare. Anne Maitland receives compensation as part of the speakers\u2019 bureau of Sanofi Pharmaceuticals, Regeneron, and Genentech. There is no conflict of interest with the observations reported in this manuscript and Dr. Maitland\u2019s affiliation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"620"}}